Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033839 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache
A Phase 3 study of Episodic Cluster Headache, sponsored by Winston Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00033839: Completed Phase 3 study of Episodic Cluster Headache, sponsored by Winston Laboratories.
NCT00033839 is a Phase 3 study of Episodic Cluster Headache that has completed, run by Winston Laboratories. The registered enrollment target is 60 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033839, a Phase 3 study of Episodic Cluster Headache, has completed, sponsored by Winston Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
Conditions Studied
Interventions
- DRUG Civamide (Zucapsaicin)
Study Locations (20)
California
- Northern California Headache Clinic - Mountain View
- San Francisco Clinical Research Center - San Francisco
- California Medical Clinic for Headache - Santa Monica
Arizona
- Valley Neurological Headache & Research Center - Phoenix
- Neurological Associates of Tucson - Tucson
Michigan
- Michigan Headache Pain & Neurological Institute - Ann Arbor
- Henry Ford Hospital Department of Neurology - Detroit
Missouri
- Mercy Health Research - Chesterfield
- Headache Care Center/Clinvest - Springfield
Ohio
- Cincinnati Headache Clinic - Cincinnati
- Cleveland Clinic Foundation - Cleveland
Connecticut
- New England Center for Headache, PC - Stamford
Florida
- Neurology Clinical Research, Inc. - Plantation
Georgia
- Neurology and Headache Specialists of Atlanta - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
What the finished NCT00033839 record still lists
NCT00033839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Episodic Cluster Headache appearing as the primary indexed condition, and to 1 intervention - of which Civamide (Zucapsaicin) is the first listed.
NCT00033839 names 20 study sites across 14 states, led by California, Arizona, Michigan.
Frequently Asked Questions
What is clinical trial NCT00033839 about?
NCT00033839 is a clinical study titled "A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache". This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
What is the current status of trial NCT00033839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2002-01. Estimated completion is 2003-07.
What conditions does trial NCT00033839 study?
This clinical trial studies the following conditions: Episodic Cluster Headache.
What interventions are being tested in trial NCT00033839?
The interventions under investigation include: Civamide (Zucapsaicin) (DRUG).
Who is sponsoring clinical trial NCT00033839?
This trial is sponsored by Winston Laboratories, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033839 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00033839's enrollment target sits among peer trials
60 1804th of 2000 higher than 177 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia